StemSight aims to cure blindness with off-the-shelf regenerative cell therapies based on hypo-immune, allogeneic induced pluripotent stem cells (iPSCs) and degradable biomaterial carriers. StemSight's lead product, STE-101, is a high-purity limbal stem cell preparation used to restore the stem cell function and the corneal epithelium in patients with limbal stem cell deficiency (LSCD), a rare disease with a significant unmet need.